Clinuvel Pharmaceuticals (ASX:CUV) refocused resources to prioritize its three key areas of clinical development: vitiligo, adrenocorticotropic hormone, and porphyrias, according to a Monday filing with the Australian bourse.
The decision is based on the need to optimize the company's internal resources, the likelihood of reimbursement for treatments, and new clinical guidelines related to central nervous system disorders.
The company also temporarily suspended its clinical programs in stroke, Parkinson's disease, and xeroderma pigmentosum, the filing said.
Clinuvel Pharmaceuticals will also continue to develop its non-pharmaceutical photocosmetic products.
The company's shares fell almost 1% in recent Monday trade.
Price (AUD): $13.20, Change: $-0.08, Percent Change: -0.60%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.